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Objective: The aim of this study was to obtain kinetic data that can be used in human risk assessment of titanium
dioxide nanomaterials.
Methods: Tissue distribution and blood kinetics of various titanium dioxide nanoparticles (NM-100, NM-101, NM-102,
NM-103, and NM-104), which differ with respect to primary particle size, crystalline form and hydrophobicity,
were investigated in rats up to 90 days post-exposure after oral and intravenous administration of a single or
five repeated doses.
Results: For the oral study, liver, spleen and mesenteric lymph nodes were selected as target tissues for
titanium (Ti) analysis. Ti-levels in liver and spleen were above the detection limit only in some rats. Titanium
could be detected at low levels in mesenteric lymph nodes. These results indicate that some minor absorption
occurs in the gastrointestinal tract, but to a very limited extent.
Both after single and repeated intravenous (IV) exposure, titanium rapidly distributed from the systemic
circulation to all tissues evaluated (i.e. liver, spleen, kidney, lung, heart, brain, thymus, reproductive organs). Liver
was identified as the main target tissue, followed by spleen and lung. Total recovery (expressed as % of nominal
dose) for all four tested nanomaterials measured 24 h after single or repeated exposure ranged from 64-95% or
59-108% for male or female animals, respectively. During the 90 days post-exposure period, some decrease in
Ti-levels was observed (mainly for NM-100 and NM-102) with a maximum relative decrease of 26%. This was
also confirmed by the results of the kinetic analysis which revealed that for each of the investigated tissues the
half-lifes were considerable (range 28–650 days, depending on the TiO2-particle and tissue investigated). Minor
differences in kinetic profile were observed between the various particles, though these could not be clearly related
to differences in primary particle size or hydrophobicity. Some indications were observed for an effect of crystalline
form (anatase vs. rutile) on total Ti recovery.
Conclusion: Overall, the results of the present oral and IV study indicates very low oral bioavailability and slow tissue
elimination. Limited uptake in combination with slow elimination might result in the long run in potential tissue
accumulation.
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Titanium dioxide (TiO2) is primarily used as a whitening
agent due to its brightness and resistance to discolor-
ation in consumer products and food. Titanium dioxide
is approved as a white-colored food additive in Europe
(E171) [1]. Examples of foods with a high content of ti-
tanium dioxide are chewing gums and candies. Personal
care products like toothpastes, lip balms, shampoos, de-
odorants and sunscreens often contain titanium dioxide
as ingredient [2,3]. Analysis by transmission electron mi-
croscopy (TEM) of one single batch of food-grade E171
titanium dioxide by Weir et al. showed that 36% of the
particles (number-based) have a particle size smaller than
100 nm [2]. Using scanning electron microscopy (SEM)-
analysis of 7 food-grade E171 titanium dioxide types,
Peters et al. reported that about 10% of the particles
(number-based) have a size smaller than 100 nm [4]. It
should be noted that both according to the data of
Weir et al. [2] and Peters et al. [4], E171 would not be
considered as a nanomaterial according to the EU Rec-
ommendation [5]. In addition, the nano-form of titan-
ium dioxide is recently also applied in paint as an
antimicrobial agent due to its hydroxyl radical genera-
tive property [6]. In some products such as sun screens
titanium dioxide can be mainly applied as nanoparticles,
whereas in many other products in which titanium di-
oxide is applied as whitening agent only fractions of the
particles are of nanosize [2,4,7].
For human risk assessment purposes, information on the
kinetics of titanium dioxide in the human body is essential.
This is particularly the case for chemicals with a potency
to accumulate with normal use. The overall resultant of ab-
sorption, distribution, metabolism and excretion (ADME),
i.e. internal exposure, will determine target tissue doses
upon human exposure to chemicals and this internal ex-
posure will be critical for the ultimate systemic adverse
health effects. In case of no absorption, the potential risk
upon exposure is expected to be limited to local effects at
the exposure site. Information on kinetics, particularly in-
ternal exposure in time, facilitates comparison between
toxicity studies with typical human situations.
Human exposure to titanium dioxide nanoparticles can
occur via various routes. For consumers, based on poten-
tial external exposure via consumer products, the oral and
dermal routes are considered most relevant. Oral exposure
may occur as regularly consumed food products contain
E171. Although the additive E171 cannot be considered as
a nanomaterial according to the current recommendation
for a nanodefinition, exposure and uptake of the nano-
fraction of E171 cannot be excluded. In addition, oral expo-
sure to consumer products such as lip balm containing
titanium dioxide and swallowing of (nano)particles after inha-
lation exposure and transport via the muco-ciliary escalator
to the mouth, might contribute to the total oral exposure.Information on the extent of oral absorption of these particles
provides information on whether internal exposure is
possible. Furthermore, information on the kinetic profile,
i.e. what are the target tissues, and to which extent does
elimination from the target tissues occur, provides insight
in the potential to accumulate in specific tissues in
daily use.
In general, nanomaterials rapidly distribute from blood
to tissues [8-11]. Particularly, highly perfused reticulo-
endothelial system (RES)-containing tissues such as liver,
and spleen are target tissues for nanomaterials. Distri-
bution across protecting membranes has also been
observed as nanoparticles have been detected, though in
low quantities, in brain, fetus and testis, whereas the
presence of nanoparticles in the brain might also occur
after inhalation via the olfactory route [12]. Furthermore,
elimination is in general quite slow, and for metal and
metal oxide nanoparticles like titanium dioxide meta-
bolic degradation does not seem to occur. Elimination of
these materials may rather be related to dissolution,
which can be very slow. Limited elimination in combi-
nation with a low fraction that becomes systemically
available will eventually result in accumulation in tissues
upon repeated exposure.
Some knowledge on the kinetics or tissue distribution
of titanium dioxide nanoparticles upon exposure via
various routes (oral, intravenous, dermal and inhalation)
is already available [13,14]. However, information for
oral absorption and the elimination from tissues follow-
ing longer time periods are limited. In other studies,
tissue distribution after exposure via the various routes
was found to be mostly to liver, kidney, spleen and lungs
[15-24]. Dermal absorption of nano- or micro- titanium
dioxide in vivo (humans, animals) or in vitro (porcine or
human skin) is very low, mostly resulting in values below
the detection level [24-28]. One study reported systemic
bioavailability after dermal exposure [23]. However, doubts
were expressed on the results because of deficiencies in the
(reported) characterization, high values of Ti in the control
group and most importantly the study design could not
exclude oral intake [29].
Absorption of titanium dioxide showed differences
among the various exposure routes. Recently, results of
an oral 13-week repeated dose study showed low oral
absorption of titanium dioxide nanoparticles (based on
limited increased blood and tissue titanium levels; not
further quantified) [30]. Furthermore, there is little know-
ledge on the differences in kinetics between different
titanium dioxide nanomaterials and how this relates to
physicochemical characteristics such as size.
The aim of this study was to obtain better kinetic input
for human risk assessment of titanium dioxide nano-
materials. Titanium dioxide particles with different size-
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repeated (5x) dose study in rats. These materials are all
commercially manufactured and available via the JRC
repository (EU Joint Research Centre (JRC), Ispra, Italy).
Both intravenous and oral administration routes were
investigated. The oral route was applied as this was con-
sidered a relevant exposure route for consumers/general
population. The intravenous route was included to obtain
insight into the tissue distribution and elimination profile
of titanium dioxide particles under conditions of 100%
systemic bioavailability, which also makes it possible to
obtain a reliable concentration-time relation of Ti in blood
and multiple tissues. Dose levels that are considered reali-
stic and relevant for human exposure were applied in our
study. Finally, based on general kinetic behavior of nano-
materials and the relevance for risk assessment, emphasis
was furthermore put on the potential long elimination
period and therefore a 90-day recovery period was
included in the present study.0
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Figure 1 Oral study: Hydrodynamic number size distribution
of NM-101/NM-102/NM-103/NM-104 of the suspended TiO2
particle preparations used for oral gavage (A: results for
particle size 0–250 nm; B: results for particle size 0–3000 nm).
The majority of particles were observed as agglomerates/
aggregates between 50–200 nm. Suspensions of NM-101 and
NM-102 contained an additional mode between 250 and 2500 nm.
No agglomerates/aggregates were observed above 3 μm. Results are
the mean of 12 analyses conducted on two separate days.Results
Characteristics of titanium dioxide test materials
Oral study
The number size distribution of the suspended TiO2 par-
ticle preparations used for oral gavage was characterized
by dynamic light scattering (DLS).
All TiO2 containing suspensions gave reliable results
when analyzed according to the DTS software (Table 1).
The majority of particles occurred as agglomerates/
aggregates measuring between 80–150 nm (peak num-
ber distributions, Figure 1). Suspensions of NM-103,
and NM-104 contained the smallest agglomerates/aggregates
(80–90 nm) whereas the largest were observed with NM-101
and NM-102 (140–150 nm). NM-101 and NM-102 additio-
nally showed a bi-modal size-distribution with another much
less frequent mode of ~1 μm. No particles were observed
between 3 μm and 10 μm (the upper limit of the Zetasizer
nano ZS) for any of the materials.Table 1 Z-average (intensity distribution peak) and







NM-101 2.56 EtOH/RSA/PBS 278.49 ± 7.7 0.32 ± 0.03
NM-102 2.56 EtOH/RSA/PBS 366.83 ± 13.64 0.29 ± 0.00
NM-103 2.56 EtOH/RSA/PBS 127.18 ± 0.42 0.38 ± 0.01
NM-104 2.56 EtOH/RSA/PBS 107.73 ± 3.85 0.27 ± 0.00
control 2.56 EtOH/RSA/PBS unreliable
results*
0.82
*due to the high PI.
Results are the mean ± SD of 12 analyses conducted on two separate days.IV study
Particle tracking with the NanoSight equipment was per-
formed for NM-100, NM-102, NM- 103 and NM-104
used for the IV studies. The evaluation was performed
just after the dispersions were prepared. Representative fig-
ures are presented for NM-100 and NM-102 (Figures 2A
and B, respectively). For NM-100 one single peak was
observed at the nominal size of the particle diameter
(200–220 nm). For NM-102 different peaks could be
identified indicating the presence of polydispersity of the
initial sample (multiple sizes) or the occurrence of
agglomeration/aggregation of the individual nano-
particles into larger agglomerates/aggregates of nano-
particles. Agglomerates/aggregates of nanoparticles with a
size of approximately 60 nm, 100 nm, 160 nm, and
250 nm could be identified by the observed peaks.
Tissue distribution of titanium dioxide particles after oral
dosing
For the oral administration liver, spleen and mesenteric























































Figure 2 IV study: Hydrodynamic particle number size distribution
of (A) NM-100 and (B) NM-102. Analysis was performed with the
NanoSight particle tracking equipment. Mean of 3 independent
measurements.
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102, NM-103, and NM-104 was evaluated for the repeated
dose schedule only. All liver and spleen tissue samples from
rats (NM-101: male and female rats, NM-102, NM-103 and
NM-104: male rats) exposed five times contained very low
titanium levels, with levels mostly below the limit of detec-
tion of 0.03 μg/g (Table 2). In exposed animals, twenty-
eight measurements were below the LOD (0.03 μg/g
tissue), 1 was at the LOD (NM-102 liver) and 1 was above
the LOD (male liver NM-103). In control animals twice a
measurement at the LOD was observed, while 10 times the
level was below the LOD.Table 2 Ti-levels (μg Ti/g tissue) in liver and spleen tissue sam
Liver
Dose (mg) Animal 1 Animal 2
Control 5x 0 ♂ < 0.03 < 0.03
NM-101 5x 2.304 ♂ < 0.03 < 0.03
NM-102 5x 2.304 ♂ < 0.03 0.03
NM-103 5x 2.304 ♂ 0.08 < 0.03
NM-104 5x 2.304 ♂ < 0.03 < 0.03
Control 5x 0 ♀ < 0.03 < 0.03
NM-101 5x 2.304 ♀ < 0.03 < 0.03All samples of MLN tissue contained amounts above
the limit of detection (Figure 3). Lowest detected concen-
tration was 0.07 μg Ti/g MLN (left panel) or 0.11 μg Ti
for the whole MLN (right panel), well above the LOD.
Titanium levels in MLN of TiO2 exposed animals were,
except for NM-104, similar to control animals. It appears
that female rats (control and NM-101) have a slightly
higher Ti concentration in MLN determined per g/MLN,
probably due to a lower weight of MLN and higher rela-
tive dosing of TiO2. MLN of females and males weighed
on average 1.08 g and 1.56 g, respectively. This means
that μg Ti are similar when mentioned/g or for the
whole MLN for females.
In view of the low levels measured after the repeated
administration (Table 2), organs of the single dose sche-
dule were not analysed.
The results indicate that after oral administration
absorption of TiO2 is very low.
Tissue distribution of titanium dioxide nanoparticles after
IV administration
Data of male and female animals will be presented and
described separately in this paragraph, though the focus
will be on the male animals. In general, female animals
showed a similar kinetic profile as male animals. A sup-
plementary file is provided containing a full overview of
the titanium data of female animals (i.e. titanium levels
expressed as μg/g tissue).
Titanium levels in control (vehicle-exposed) animals
were near and below the detection limits in all investi-
gated tissues.
The blood kinetics of IV-administered titanium di-
oxide (single and repeated exposure) in male rats are
presented in Figures 4A and B. Analysis of titanium in
blood revealed a rapid decline of titanium levels. After
the initial rapid decline (within <0.5 hour), the plasma
titanium levels remained constant with only a small
decrease during post-exposure periods of up to 14 days
(data not shown).
After single administration, titanium could be detected
at the first tissue measurement point (i.e. 24 hours afterples of orally-treated rats
Spleen
Animal 3 Animal 1 Animal 2 Animal 3
< 0.03 < 0.03 < 0.03 < 0.03
< 0.03 < 0.03 < 0.03 < 0.03
< 0.03 < 0.03 < 0.03 < 0.03
< 0.03 < 0.03 < 0.03 < 0.03
< 0.03 < 0.03 < 0.03 < 0.03
0.03 < 0.03 < 0.03 0.03
< 0.03 < 0.03 < 0.03 < 0.03
Figure 3 Oral study: Determination of Ti concentration in gut
mesenteria with mesenteric lymph nodes (designated MLN)
from rats exposed via the oral route on 5 consecutive days for
either control or TiO2-suspensions. Ti-concentrations are illustrated


















































































Figure 4 IV study: Blood kinetics of Ti (μg Ti/g blood) after single IV (
NM-104 in male rats. Insert: blood kinetics during the first two hours
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those as measured in control (vehicle-treated) animals
(Figure 5, male animals). Repeated exposure to all titan-
ium dioxide nanomaterials was found to result in up to
5 times higher tissue titanium levels (expressed as μg/tissue)
compared to single dose, indicating that during this time
frame no significant elimination occurred and a dose
proportional accumulation occurred (Figure 5 and Figure 6,
male animals). This also becomes apparent when expressing
the titanium levels as % of the dose administered, no clear
differences in titanium-levels were observed at 24 hours
after the last dosing (Figure 7 (male) or 8 (female) single vs.
repeated exposure).
Figure 7 and Figure 8 show the recovery for each in-
vestigated tissue as percentage of the dose administered
at 24 h after the last administration for male and female
animals respectively. After single dosing, the highest
tissue distribution in males was observed (in descending
order) in liver, spleen and lung for all titanium dioxide









































































NM-100 NM-102 NM-103 NM-104
Figure 5 IV study: Organ distribution (μg/organ) of Ti on Day 2 after single IV dosing with NM-100, NM-102, NM-103 and NM-104 in
male rats (LOD: 0.05 μg/g). A: liver, spleen and lungs, B: kidney, heart, brain, thymus, blood and testis. NM-100: brain < LOD. NM-102: brain < LOD.
NM-103: blood and testis < LOD. NM-104: brain, blood and testis < LOD.
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tissues contained less than 0.3% of the dose administered.
In female animals, highest titanium levels were also found
in liver, spleen and lung tissue for all titanium dioxide
nanomaterials, with recovery per tissue of 59-104%, 1.3-
2.6% and 0.4-2.0%, respectively. Also after repeated dosing,
highest tissue levels were found in liver, spleen and lung.
The results of the recovery for each of the investigated
tissues at day 90 after single and repeated dosing are
presented in Figure 9 and Figure 10 for male and female
animals respectively. In general, also liver, spleen and lung
tissue showed the highest tissue distribution.
An overview of the total recovery (amount titanium in
sampled tissue expressed as % of the total administered
dose) after single and repeated dosing with NM-100, NM-
102, NM-103 and NM-104 for both males and females is
shown in Table 3. Total recovery at 24 hours after single
administration ranged from 64-95% and 59-108% for male
and female animals respectively. NM-103 (females) and
NM-104 (males) showed the highest total recovery (108%
and 95%, respectively) at this time point after single do-
sing. Total recovery as measured at 24 hours after the last
administration in the repeated exposure groups ranged
from 66-95% and 65-88% for male and female animals,respectively. Also NM-103 (male: 95%, female: 88%) and
NM-104 (female: 88%) showed highest total recovery at
day 90 after repeated dosing.
Both after single and repeated titanium dioxide IV
administration (NM-100, NM-102, NM-103, NM-104),
titanium levels in faeces (collected at days 2, 6, 14, 30 or
90 if possible), obtained at the same time as the tissues
were collected, were similar to those observed in vehicle
control animals (data not shown). In addition, no
increase in titanium levels in urine (collected at days 2,
6, 14, 30 or 90 if possible) was observed after repeated
exposure in NM-100 and NM-102 exposed animals (no
analysis performed in urine of NM-103 and NM-104
exposed animals). This is in agreement with the negli-
gible elimination.
For both the single as well as the repeated IV expo-
sure, the potential elimination of titanium was measured
up to 90 days post-exposure. During this post-exposure
period, some decline was observed (mainly for NM-100
and NM-102) with a maximum decrease of 20% (NM-
100, males) (Table 3), which corresponds to a maximum
relative decrease of 26% (day 90 vs. day 2 or 6). For liver
and spleen, these results are shown in Figure 11 (single























































NM-100 NM-102 NM-103 NM-104
Figure 6 IV study: Organ distribution (μg/organ) of Ti on Day 6 after repeated IV dosing with NM-100, NM-102, NM-103 and NM-104 in
male rats (LOD: 0.05 μg/g). A: liver, spleen and lungs, B: kidney, heart, brain, thymus, blood and testis.
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post-exposure for all titanium dioxide particles together
with increased spleen titanium levels. At day 90 post-
exposure, titanium levels in spleen were higher as com-
pared to liver titanium levels (expressed as μg/g tissue).
This indicates some redistribution between liver and
spleen.
Further, data of female animals (titanium levels expressed
as μg/g tissue) are presented separately as Additional file 1:
Tables S1-S8. In general, female animals showed a similar
kinetic profile as male animals. The major difference
between male and female animals was the disappearance
of Ti in the reproductive organs, which was slower in
female animals.
Table 4 presents the results of the kinetic analysis. The
results show very long elimination half-lifes for each of
the investigated tissues. Further, some differences in
Cmax and AUClast are observed between materials, with
in general NM-103 and NM-104 showing the highest
values.
Discussion
The present study describes the kinetics of titanium di-
oxide nanoparticles in rats. Animals were exposed via either
the oral or the IV route. As exposure via food-productsmight contribute significantly to the total exposure of titan-
ium dioxide nanoparticles, evaluation of the absorption
from the oral route is relevant for human risk assessment.
The IV route was included to obtain insight in the blood
and tissue distribution profile under conditions of full
systemic bioavailability, and to gain insight in the elimi-
nation over a prolonged period of time (90 days).
Oral absorption (oral study)
The dose levels used in our oral study (i.e. 2.3 mg TiO2/
animal/day for five days; 6.8-8.5 mg TiO2/kg bw/day for
male animals and 10.9-12.0 mg TiO2/kg bw/day for
female animals) are much lower and more realistic than
doses used by others in toxicity or kinetic studies, as
these typically applied doses greater than 100 mg/kg bw/
day and even as high as several thousands of milligrams
TiO2/kg bw/day [15,30]. The consumption of titanium
dioxide for the UK population was reported to be on
average 2–3 mg/kg bw/day for children under the age of
10 years and approximately 1 mg/kg bw/day for other
consumer age groups [2]. For USA, these numbers were
1–2 mg/kg bw/day and 0.2-0.7 mg/kg bw/day respec-
tively [2]. The dose levels used in our oral study can thus












































































































































































































single dose repeated dose
single dose repeated dose
single dose repeated dose
Figure 7 IV study: Organ distribution of Ti as percentage of administered dose at 24 h after the last dosing after single (i.e. Day 2) and
repeated (i.e. Day 6) IV dosing with NM-100, NM-102, NM-103, and NM-104 in male rats. (LOD: 0.05 μg/g). left: liver, spleen and lung,
right: kidney, heart, brain, thymus, blood and testes. NM-100: brain (single exposure) < LOD. NM-102: brain (single exposure) < LOD. NM-103: blood
and testis (all single exposure) < LOD. NM-104: brain, blood and testis (all single exposure) < LOD.
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all dose of 11.5 mg TiO2) titanium levels were near or
below the detection limit in liver and spleen, indicating a
very low absorption. Because of the realistic dose levelsused in the present study, a quantitative value for oral
absorption is difficult to determine due to the many
measurement points below the LOD. Only in two out of




























































































































































































































Figure 8 IV study: Organ distribution of Ti as percentage of administered dose at 24 h after the last dosing after single (i.e. Day 2)
and repeated (i.e. Day 6) IV dosing with NM-100 (A), NM-102 (B), NM-103 (C), and NM-104 (D) in female rats. (LOD: 0.05 μg/g).
Left: liver, spleen and lung, Right: kidney, heart, brain, thymus, blood and ovaria. NM-103: blood (single exposure) < LOD. NM-104: blood and brain
(single exposure) < LOD.
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In contrast all MLN samples (controls and exposed)
contained Ti amounts above LOD (Figure 3). Only a
small increase in Ti content was observed, because the
background levels in MLN were 2–3 times the LOD.
MLN from control rats contained 0.14 μg Ti whereas
the highest Ti average was 0.36 μg and was located in
MLN from NM-104 exposed rats. This gives an increase
of 0.226 μg Ti in MLN or 0.003% of the 6895 μg Ti ex-
posure in the dose.
The total recovery of dosed Ti in all tested organs
(expressed as % of the total dose) was estimated to be
approximately 0.02%. This was based on calculations
using different scenarios (i.e. using LOD or half the
LOD for the non-detects; correcting the tissue levels for
background levels; using only the positive liver titanium
levels). Not all tissues were included as the oral study fo-
cused on liver, spleen and mesenteric lymph nodes as
target tissues, which seems appropriate based on the re-
sults of the IV study. The data of our oral study indicate
that some minor absorption may occur in the GI tract
after oral exposure, be it to a very limited extent. How-
ever, due to the very limited elimination of the nano-
particles even a low absorption should be considered in
risk assessment.
Recently, Tassinari et al. (2014) [31] evaluated, in addition
to the reproductive and endocrine effects of nano-sized
titanium dioxide particles (commercially available, anatase,
primary size < 25 nm, BET surface area 45–55 m2/g), Ti
levels in tissues as thyroid, ovaries and spleen after short-
term exposure [31]. Rats were orally exposed for 5 days to
0, 1 or 2 mg/kg bw/day titanium dioxide nanoparticles
(doses which are even lower than the doses as applied in
our study). A significant increase in titanium levels in
spleen (0.046 ± 0.008 μg/g) was observed at the high dose
group, though the difference with the control animals
was small. These data are in the same range as inci-
dentally observed in our study. Single particle-ICP-MS
analysis of the target tissue spleen revealed the pres-
ence of both titanium dioxide nanoparticles and their
aggregates [31]. The kinetics of nano-sized titanium
dioxide in rats after repeated 13-weeks oral exposure
were studied by Cho et al. [30]. Titanium dioxide par-
ticles (commercially available, primary particle size of
26.4 ± 6.1 nm as measured with SEM) were adminis-
tered to rats in doses of approximately 250, 500 and
1000 mg/kg bw/day, 7 days/week for 13 weeks. Titanium-
levels were analyzed using ICP-MS with a reported limit
of detection of 0.1-1 ng/L. No clear dose-related increases
in titanium levels in liver, spleen, kidney and brain could
be observed, indicating very low systemic bioavailability
[30]. At high dose levels such as several hundreds to one
thousand milligram/kg bw/day, absorption of titanium di-
oxide might be reduced due to agglomeration/aggregationof the particles in the gastrointestinal tract. For silica parti-
cles, it was recently hypothesized that gel-formation oc-
curs, especially at higher particle concentrations, under
conditions of a relatively high pH and salt concentration,
like in the intestine [32]. This gelation is hypothesized to
lead to a decrease in oral absorption with increasing dose.
In contrast, Wang et al. showed absorption of titanium
dioxide nanoparticles after a single high dose oral expo-
sure in mice [15]. They used a very high and quite un-
realistic single dose of 5000 mg/kg bw (approximately 100
times higher than the cumulative dose used in our study).
Primary particle size of the titanium dioxide particles
included in this study was 25, 80 and 155 nm. After a sin-
gle oral dose, titanium could be detected in liver, spleen,
kidney, lung, brain and red blood cells. They identified
liver as the main target tissue, where highest uptake (by
far) was shown for the 80 nm particle (approximately
4 μg/g; a concentration about 100 times higher than our
LOD) [15].
Tissue distribution (IV study)
Based on the results of our IV study, liver, spleen and
lungs were identified as primary target tissues for titan-
ium dioxide nanomaterials. Highest levels were observed
in the liver, but redistribution of the liver to the spleen
was observed over the 90 day post-exposure period. A
similar kinetic profile after 24 hours for titanium dioxide
nanoparticles in rats was observed recently [17,22]. In
these studies, a single IV administration of titanium di-
oxide nanoparticles (5 mg/kg bw) resulted in highest
levels (in descending order) in liver, spleen, lung and
kidney as well [17,22]. After IV administration, titanium
levels in blood rapidly declined (both after single as well
as repeated administration). These results indicate a fast
distribution of titanium dioxide to the various tissues.
The tissue distribution profiles of the four IV tested
nanomaterials with different sizes and crystalline forms
(NM-100, NM-102, NM-103, NM-104) are in general
rather similar, although some differences were observed.
Titanium was detected in all investigated tissues in the
present study, i.e. blood, liver, spleen, kidney, lung, heart,
brain, thymus and reproductive organs. The total reco-
very was mainly below 100%. An explanation might be
that not all tissues were investigated. Skin and muscle
were not included as they were inconsequently mea-
sured or an initial experiment showed that the levels
were close to the detection limit (data not shown). Bone
marrow Ti levels could not be measured due to the
small sample size. Based on the relatively constant tissue
and low blood levels (after the initial rapid decline), it
seems rather unlikely that the incomplete recovery can
be explained by elimination processes. This is in agree-
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Figure 9 IV study: Organ distribution of Ti as percentage of administered dose on Day 90 after single and repeated IV dosing with
NM-100 (A), NM-102 (B), NM-103 (C), and NM-104 (D) in male rats. (LOD: 0.05 μg/g). Left: liver, spleen and lung, Right: kidney, heart, brain,
thymus, blood and testes. NM-100: brain (single), blood (single + repeated), testis (repeated) < LOD. NM-102: brain (single), blood (single + repeated),
testis (single + repeated) < LOD. NM-103: brain (single), testis (single + repeated) < LOD, blood (single + repeated): not measured. NM-104: brain (single),
testis (single + repeated) < LOD, blood (single + repeated): not measured.













































































































































































































Figure 10 IV study: Organ distribution of Ti as percentage of administered dose on Day 90 after single and repeated IV dosing with
NM-100 (A), NM-102 (B), NM-103 (C), and NM-104 (D) in female rats. (LOD: 0.05 μg/g). Left: liver, spleen and lung, Right: kidney, heart, brain,
thymus, blood and ovaria. NM-100: brain (single exposure) < LOD, blood (single + repeated) < LOD. NM-102: brain + ovaries (single exposure) < LOD,
blood (single + repeated) < LOD. NM-103: brain (single exposure) < LOD, blood (single + repeated): not measured. NM-104: brain (single exposure) < LOD,
blood (single + repeated): not measured.
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female animals were observed. The major difference
between male and female animals was the disappearance
of Ti in the reproductive organs. In male animals Ti was
not detectable in the testes 30 days after administration,
whereas at day 90 Ti was still detectable in the female
ovaries. This difference can be explained by the diffe-
rences in blood supply to the testes and ovaries. On day
6 a similar very low percentage of the dose was distri-
buted to both testes and ovaries.
Elimination (IV study)
Both after single and repeated IV exposure, blood titan-
ium levels in blood decreased rapidly during the first
minutes after which the titanium levels slowly decreased
and approached the limit of detection at 24 hours post-
dose, similar to what was found earlier for silver nano-
particles in blood by Lankveld et al. [8]. In the nanosilver
study the sampling period ranged to 17 days instead of
90 days as was the case in our study. During the period
of 12 days after exposure, Lankveld et al. found a gradual
decrease in organ silver levels but silver was still present
in several organs including liver, lungs, spleen and kidney
[8]. In our study, the total titanium levels slowly, but
definitely, reduced up to Day 90, although such a decreaseTable 3 Recovery of titanium for male and female rats in
the summed investigated organs* as percentage of dose
administered after single or repeated dosing
Day 2/6** Day 14 Day 30 Day 90
Single
NM-100 Male 75 ± 3 nd nd 55 ± 3
Female 72 ± 8 nd nd 57 ± 1
NM-102 Male 64 ± 4 nd nd 52 ± 5
Female 59 ± 6 nd nd 53 ± 1
NM-103 Male 86 ± 17 nd nd 91 ± 12
Female 108 ± 8 nd nd 103 ± 12
NM-104 Male 95 ± 18 nd nd 109 ± 7
Female 89 ± 5 nd nd 100 ± 4
Repeated
NM-100 Male 71 ± 8 69 ± 4 70 ± 4 59 ± 5
Female 73 ± 6 nd nd 61 ± 7
NM-102 Male 66 ± 14 69 ± 6 70 ± 3 54 ± 1
Female 65 ± 8 nd nd 55 ± 1
NM-103 Male 95 ± 6 110 ± 21 96 ± 19 72 ± 13
Female 88 ± 7 nd nd 84 ± 3
NM-104 Male 75 ± 5 99 ± 3 81 ± 10 77 ± 6
Female 88 ± 10 nd nd 86 ± 4
*liver, spleen, kidney, lung, heart, brain, thymus, blood, testes/ovaries.
**Day 2 or day 6 corresponds to single or repeated dosing respectively.
nd: not determined.is not obvious from the data at time point day 14 (i.e. 9 days
after exposure). Based on these data it can be concluded
that elimination of total TiO2 has a long half-life, which
was also shown by the results of the kinetic analysis
presenting half-life in days for the various organs (for
example for liver as the main target organ: 28–248 days).
In contrast to the titanium dioxide particles, as described
here, for NM-105 (an anatase rutile mixture) a major
decline in various organ levels was noted [33]. In the
present study, some reduction in recovery was observed up
to Day 90 for the pigment-sized (NM-100) and one of the
nano-sized (NM-102) titanium dioxide particles, with a
maximum relative decrease (day 90 vs. day 2 or 6) of 26%
(NM-100, males).
Redistribution of titanium from the liver to the spleen
was observed between Day 2/Day 6 and Day 90, whereas
redistribution to remaining tissues was not identifiable.
Release of particles from liver and possibly other organs
may be responsible for the increase in spleen levels. The
data show that at the long run TiO2 particles will ac-
cumulate in spleen. The spleen Ti concentration rises
during the entire exposure, including the 90 day post
exposure period.
In addition, titanium levels as measured in the faeces
of IV-treated (single and repeated) animals revealed no
clear differences between titanium dioxide-exposed
animals and vehicle-treated controls (data not shown).
Further, no increase in titanium levels in urine was
observed. This further confirms the lack of elimination of
the titanium dioxide nanoparticles.
The expected accumulation with daily exposure as a
consequence of the negligible elimination might indicate
a potential concern for human health risk. Even with
very low uptake from the gastrointestinal tract human
daily oral exposure can be expected to give rise to a very
low but steady increase in titanium levels in tissues in
time. Weir et al. estimated the exposure to pigment grade
TiO2 via food in the order of 1 mg/kg bw per day [2]. The
nanofraction in these pigmentary TiO2 (E171) is estimated
to be 10-36% of the number of particles [2,4]. So, the as-
pects of oral uptake, limited elimination and anticipated
accumulation in man should be further investigated in the
risk assessment of nanosized TiO2.
Differences between titanium dioxide particles tested
The present study is the first to evaluate the kinetics of
different titanium dioxide nanoparticles after both single as
well as repeated oral and intravenous administration in rats.
The titanium dioxide nanoparticles as used in this study
differed with respect to particle size, with NM-100 being
the largest particle (nominally 200–220 nm vs. 7–10 nm for
NM-101, 15–25 nm for NM-102 and, 20 nm for NM-103
and NM-104). However it should be realized that in the































































































Figure 11 IV study: Distribution of Ti to the liver and spleen (μg Ti/g organ) after single IV dosing with NM-100 (A), NM-102 (B), NM-103
(C), and NM-104 (D) in male rats.
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aggregates (more or less fixed particles). Only minor diffe-
rences in kinetic profile, both after single and repeated
exposure, were observed in the present study, which may
be linked to differences in size, hydrophobicity, crystalline
form or just animal or random variation. For gold nano-
particles we previously observed a difference in tissue
distribution depending on size, the smaller nanoparticles








































Figure 12 IV study: Distribution of Ti to the liver and spleen (μg Ti/
NM-103 (C), and NM-104 (D) in male rats.In the present study, all particles showed a rapid distri-
bution to the organs from the systemic circulation. The
total recovery of NM-103 and NM-104 was higher than
NM-100 and NM-102, which might indicate a small diffe-
rence in tissue distribution. Some indications were noted
for a difference in recovery between anatase (NM-102) and
rutile nano-TiO2 (NM-103 and NM-104). However, these
crystalline forms were not compared in one single expe-








































g organ) after repeated IV dosing with NM-100 (A), NM-102 (B),
Table 4 Basic pharmacokinetic parameters of titanium dioxide in different organs after 5 daily administrations of TiO2
by the IV route
NM Organ β T1/2el Ct AUClast
(/d) (d) (μg/g)* (μg d/g)**
NM-100 liver 0.0028 248 522.3 ± 23.34 (t = 6) 32790 ± 2306
NM-102 liver 0.0073 95 485.3 ± 62.13 (t = 6) 34682 ± 1195
NM-103 liver 0.0129 54 727.3 ± 64.72 (t = 14) 45919 ± 3684
NM-104 liver 0.0250 28 694.0 ± 10.82 (t = 14) 43491 ± 855
NM-100 kidney 0.0058 120 1.29 ± 0.09 (t = 6) 41 ± 4
NM-102 kidney 0.0047 146 1.45 ± 0.06 (t = 6) 69 ± 2
NM-103 kidney 0.0140 49 3.69 ± 0.19 (t = 6) 190 ± 19
NM-104 kidney 0.0013 531 2.46 ± 0.59 (t = 6) 178 ± 13
NM-100 lung 0.0153 45 54.67 ± 10.27 (t = 90) 4360 ± 381
NM-102 lung 0.0091 76 120.00 ± 19.22 (t = 14) 8733 ± 647
NM-103 lung 0.0072 96 130.67 ± 4.41 (t = 6) 7817 ± 672
NM-104 lung nc nc 55.02 ± 5.20 (t = 90) 3791 ± 187
NM-100 spleen 0.0011 650 536.01 ± 37.53 (t = 90) 41175 ± 1437
NM-102 spleen nc nc 827.33 ± 33.88 (t = 90) 45909 ± 1241
NM-103 spleen nc nc 1833.67 ± 578.34 (t = 90) 102710 ± 18670
NM-104 spleen nc nc 2221.667 ± 309.47 (t = 90) 130624 ± 9527
NM-100 heart 0.0048 146 0.81 ± 0.09 (t = 6) 39 ± 1
NM-102 heart 0.0050 140 0.81 ± 0.13 (t = 14) 48 ± 3
NM-103 heart 0.0029 237 1.35 ± 0.06 (t = 6) 85 ± 14
NM-104 heart nc nc 1.50 ± 0.26 (t = 90) 78 ± 10
β = apparent elimination rate, T1/2el: apparent elimination half-life, Ct: highest concentration at time point t (day), AUClast: area under curve between the between
1st measured concentration and the last measured concentration, nc: not calculated.
*P < 0.05 NM-100/NM-102 vs NM-103/NM-104 (for all tissues).
**P < 0.05 NM-100 vs NM-103/NM-104 (for all tissues).
Geraets et al. Particle and Fibre Toxicology 2014, 11:30 Page 15 of 21
http://www.particleandfibretoxicology.com/content/11/1/30Further, elimination from the studied organs was very
slow, with no difference between the titanium dioxide
particles observed. It should be noted that in the present
study we did not systematically change a specific
physicochemical characteristic of the selected titanium
dioxide particles. Such an approach could facilitate the
detection of differences in kinetic behavior in relation
to such a characteristic. In the present study commer-
cially available titanium materials were used, which is
relevant from a risk assessment point of view. At the
moment it is not possible to combine these aspects.
Conclusions
The titanium dioxide nanoparticles evaluated in this study
showed very limited bioavailability after oral exposure,
though there was evidence that absorption is possible
in the gastrointestinal tract as increased levels of tita-
nium could be detected in some livers and mesenteric
lymph nodes in exposed animals compared to control
animals. It can be further concluded that after systemic
exposure, the titanium dioxide nanoparticles mainlydistributed to the liver, spleen and lung. Though the
studied particles differed to some extent with respect to
primary particle size, some but no major differences in
tissue distribution were observed. Repeated exposure
resulted in increased but dose-proportional tissue levels.
Tissue redistribution was observed from the liver to the
spleen over a period of 90 days after exposure, with an
increase rather than a decrease in Ti spleen concentration
during the 90 day post-exposure period. Further, elimi-
nation was very slow with only small amounts titanium
dioxide eliminated in up to 90 days post-exposure. Elimi-
nation was most pronounced for the pigment-sized
(NM-100) and one of the nano-sized titanium particles
(NM-102).
Overall, the results of the present study indicates
very low oral bioavailability and slow tissue elimi-
nation. Limited uptake in combination with slow eli-
mination might result in the long run, particularly with
daily exposure, in potential tissue accumulation. This
is especially important for the human risk assessment
of these materials.
Table 5 Characteristics* of titanium dioxide nanomaterials
NM-100 NM-101 NM-102 NM-103 NM-104
Use Pigment (multiple) Photocatalyst Photocatalyst Cosmetics Cosmetics
Crystal form anatase anatase anatase rutile (hydrophobic) rutile (hydrophilic)
Nominal particle size (nm) 200 - 220 7 - 10 15 - 25 20 20
Mean particle size (nm) 267 38 132 186 67
Primary particle or crystal size (nm) 42-90 6 20 20 20
Specific surface area (m2/g) 10 320 90 60 60
*Particle characterization as described in [33,35].




Male (N = 30) and female (N = 6) Wistar rats (CRL:WI
(WU)) were obtained from Charles River, Germany.
They were delivered as 7 weeks old and were randomly
divided into groups of two males or three females. They
were housed in polycarbonate cages with a bottom area
of 905 cm2 and a height of 21.5 cm, with bedding, feed,
enrichment, light and temperature/humidity as described
previously [34]. The cages were sanitized twice weekly.
The rats were barrier maintained and were allowed to
acclimatize for 2 weeks before they entered the experi-
mental protocol. All rats were 9 weeks old at the time of
the experiment. The experiments were conducted at
NRCWE (Copenhagen, Denmark). All animal procedures
followed the guidelines for the care and handling of
laboratory animals established by the Danish government,
and the local animal welfare body as well the National
Animal Experiment Inspectorate under the Ministry of
Justice, approved the study.
IV study
Male and female Wistar rats (CRL:WI (WU)) were
obtained from Charles River, Germany. Exposure started
after 1–2 weeks of acclimatization. All rats were 9–10
weeks old at the start of the experiment. Rats were ran-
domly divided into groups of 1-3/cage. Animals were
bred under specific pathogen-free (SPF) conditions and
barrier maintained under controlled conditions of
temperature, humidity and light during the experiments.
Standard feeding chow diet and water were allowed ad
libitum. The experiments were conducted at the National
Institute for Public Health and the Environment (RIVM,
Bilthoven, The Netherlands) according to a protocol
approved by the local Ethics Committee for Animal Expe-
riments and according to European and national laws
regulating the use of laboratory animals.
Particles
Five different titanium dioxides (TiO2) were used in this
study (i.e. NM-100, NM-101, NM-102, NM-103, NM-104),
where the material numbers refer to JRC nanomaterialsrepository [35]. See Table 5 for information on the parti-
cles. Additional characterization of the test materials is
described below.
Characterisation of test material
Particle characterisation of the powder was performed as
described recently [33].
In addition, the size distribution was determined in
the dispersions used in the oral and IV studies so as to
gain insight in the quality of the dispersions used and to
get information on the exposure conditions.
Oral study
The hydrodynamic particle number size distribution of
the TiO2 particles (NM-101, NM-102, NM-103, NM-104)
in the exposure liquids were analysed by photon correlation
spectroscopy using a Dynamic laser scattering (DLS)
Zetasizer nano ZS (Malvern Inc., UK). DLS for each mate-
rial were performed on two separate days each of 6 mea-
surements. The number distributions were calculated
by the DTS software using the viscosity for H2O (0.6864),
temperature of 25°C and material refractive (Ri) and
absorption indices (Rs) for TiO2 (Anatase: Ri 2.49; Rs 0.10
and rutile: Ri 2.90; Rs 0.10). Vehicle controls were ana-
lysed using both settings. TiO2 containing and vehicle
samples were analysed using a laser attenuation factor of 2
and 7 and a measure position of 0.45 and 4.65 mm,
respectively. All samples were analysed within 30 min
after sonication, i.e. within the same time frame as the oral
exposures occurred.
IV study
The size distribution of the TiO2 particles (NM-100,
NM-102, NM-103 and NM-104) were determined
directly after preparing the suspensions for IV adminis-
tration in at least 3 separate measurements using track-
ing analysis of Brownian motion with a laser illuminated
microscopical technique (LM20, NanoSight Ltd, UK).
Test material preparation (oral and IV study)
Particle suspensions were made fresh every day according
a standardized protocol [to be published elsewhere]. Most
of our practices for ultrasonic dispersion of nanoparticle
Table 6 Schematic overview of the design of the toxicokinetic study for determination of tissue distribution of
titaniumdioxide nanomaterials
Material Daily dose (mg TiO2 /animal) # daily
doses
Route Autopsy
Day 2 Day 6 Day 14 Day 30 Day 90
NM* 2.3 1 IV 3 M + 3 F - - - 3 M + 3 F
NM* 2.3 5 IV - 3 M + 3 F 3 M 3 M 3 M + 3 F
NM* 2.3 1 Oral 3 M
NM* 2.3 5 Oral - 3 M + 3 F** - - -
Vehicle - 1 or 5 IV 2 M + 1 F 2 M + 1 F - - 2 M + 1 F
Vehicle - 1 or 5 Oral 2 M + 1 F 2 M + 1 F - - 2 M + 1 F
*NM is NM-100, NM-102, NM-103 or NM-104 for the IV route and NM-101, NM-102, NM-103, or NM-104 for the oral route.
**female animals for NM-101 only.
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Taurozzi et al. [36]. A 2.56 mg/mL stock suspension was
prepared by pre-wetting the TiO2 powder in 96% ethanol
(resulting in a final concentration of 0.5 vol% ethanol)
followed by dispersion in 0.05 wt% Rat Serum Albumin
(RSA) (Sigma #A6272) in ultrapure water. Probe sonic-
ation of the suspensions was performed on ice (Branson
Sonifier S-450D, Branson Ultrasonics Corp., Danbury,
CT, USA, equipped with a disruptor horn Model num-
ber: 101-147-037) for 16 minutes (400 W system and
used with a 10% amplitude). The stock suspensions were
diluted (9:1 v/v) with 10x concentrated phosphate buffer
pH 7.4 (702 mg NaH2PO4 x 2H2O, 4155 mg Na2HPO4 x
7H2O, dissolved in 1 L) resulting in an exposure suspen-
sion with a concentration of 2.304 mg/mL TiO2. Vehicle
control suspensions were also sonicated and diluted ac-
cording to above description. All suspensions were used
immediately. The TiO2 nanomaterials were evaluated for
the presence of endotoxin. All preparations investigated
showed endotoxin levels below 20 IU. Absence of LPS
(endotoxin) was further evaluated and confirmed by fatty
acid analysis.
Experimental protocol
Rats were treated orally or intravenously according to
the schedule as presented in Table 6. The kinetics of
NM-100 was studied for the IV route only, whereas the
kinetics of NM-101 was studied for the oral route only.
The kinetics of NM-102, NM-103 and NM-104 was
studied after both oral and IV administration.
Oral study
The rats were dosed by gavage with 1 mL of the vehicle
or TiO2-suspension according to international accepted
guidelines [37,38]. The rats were not sedated or deprived
of feed before or after administration of the test substance.
The rats were dosed using a straight metal feeding needle
with bulbed tip. The length of the inserted needle was fromlips to the last rib of the animal ensuring deposition in the
stomach. Once the needle was in place, the animal was
observed to be properly breathing before dosing 1 mL of
the TiO2 suspensions. No problems related to the exposure
(e.g. reflux or vomiting) were observed. Animals were
dosed orally either once (3 males per group, 4 TiO2
nanomaterials and controls) or during five consecutive days
(3 males per group, 4 TiO2 nanomaterials and controls; in
addition 3 females per group for NM-101 and controls).
The rats were sacrificed and tissue sampling was done 24 h
after the last exposure (Day 2 or Day 6).
IV study
The rats received a single or repeated dose of 1 mL (on
5 consecutive days) via injection in the tail vein accor-
ding to international accepted guidelines [37,38]. This
volume was frequently used in previous papers without
any problems [8-10]. Blood and tissue samples were
collected at Day 2 and Day 90 for the single IV adminis-
tration (3 male and 3 female animals per group), and at
Day 6 (i.e. the first day after the last repeated exposure),
14, 30 and 90 after the repeated IV administration (3
male and 3 female animals per group, except for Day 14
and Day 30 which included 3 male animals only). Ad-
ditional blood samples were collected via orbita punc-
ture at Day 1 (single dose) and Day 5 (repeated doses) at
5, 10, 20 and 30 minutes, and 1, 2, 4, 8, and 24 hours
after dosing in order to evaluate the elimination of Ti
from the blood after the IV administration. Control rats




The doses applied were the maximum concentration
that resulted in a stable TiO2 nanomaterial dispersion
[to be published elsewhere]. The doses are also consi-
dered to be in the realistic human exposure range [2,3].
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nanomaterials was used containing 2.3 mg TiO2 per mL.
The single dose groups received one single dose of
2.3 mg/rat corresponding to 6.8-8.6 mg/kg bw for male
rats depending on the actual weight of the rats. The
repeated dose groups received five consecutive daily
(Day 1–5) administrations of 2.3 mg TiO2 in one mL
per rat resulting in a cumulative dose range of 34.1-
42.4 mg/kg bw for male orally treated rats and 54.5-
59.9 mg/kg bw for female rats.
IV study
A dispersion of the various TiO2 nanomaterials was used
containing 2.3 mg TiO2 per mL of which 1 mL was
injected intravenously. Preliminary acute toxicity studies
(single IV dose of 2.3 mg/rat) indicated that the ma-
ximum dose was well tolerated. The single IV treated
rats received a dose of 8.4-9.8 mg/kg bw and 12.4-
14.1 mg/kg bw for male and female rats respectively. The
repeated IV treated rats received a cumulative dose that
ranged from 42.3-49.4 mg/kg bw and 61.2-71.9 mg/kg bw
for male and female rats, respectively. Thus the actual
dose in mg/kg bw depended on the weight of the rats.
Blood- and tissue sampling
Oral study
Twenty four hours after the last oral dosing the rats
were anaesthetised subcutaneously with 0.3 mL/100 g
Hypnorm® (fentanyl citrate 0.315 mg/mL and fluanisone
10 mg/mL; Janssen Pharmaceuticals)/Dormicum® (Mid-
azolam 5 mg/mL; Roche)/water mixture (1:1:2). The rats
were killed by exsanguination via the heart and the fol-
lowing tissues were collected: spleen, liver and mesen-
teria with mesenteric lymph nodes (designated MLN)
were selected as primary target tissues. Full wet weight
of these tissues was noted. However, the parts of liver
immediately surrounding the gastro intestinal (GI) tract
were not taken, since this could lead to rupture of the
GI tract and to TiO2 contamination of tissues. The full
liver weight might therefore be slightly underestimated.
Additionally, blood (450 μl weighing 0.5 g), kidney, lungs,
heart, brain, thymus, muscle, bone/bone marrow, testes or
ovaria, and skin were collected. All tissues were cooled on
dry ice and stored at −20°C.
IV study
After IV administration the rats were anaesthetized by
inhalation of isoflurane (Isoflu®, AST Pharma, Oudewater,
The Netherlands) in oxygen and subsequently euthanized
by exsanguination via the abdominal aorta. Next to blood
(0.5-1.0 mL) the following tissues were collected: liver,
spleen, kidneys, lungs, heart, brain, thymus, skin, and testes
or ovaria. Urine and feces where collected when feasible,
i.e. when present in either bladder or colon/rectum. Inaddition, lymph nodes (mesenteric and popliteal), bone
including bone marrow (femur), and muscle were collected
as well. Blood (100–200 μl) was collected via orbita punc-
ture at day 1 (for single exposure) and day 5 (for repeated
exposure) to evaluate Ti elimination from the blood circula-
tion. All tissues and blood were cooled on dry ice and
stored at −20°C.
HR-ICP-MS analysis of the tissues
The tissue distribution of the TiO2 nanomaterials ad-
ministered to the animals was evaluated by determining
the Ti content in blood and tissues at various time
points after administration by High-Resolution Induct-
ively Coupled Plasma Mass Spectrometry (HR-ICP-MS),
as recently developed and described [39]. For the oral
study, the livers were homogenized in 50 mL centrifuge
tubes for ~30 sec./level 2 using an Ultra Turrax T25
Basic (IKA Labortechnik, Staufen, Germany). Spleens and
mesenteria with lymph nodes were homogenized for
6 min in a 2 mL cryotube using a Qiagen Tissue Lyzer
at 30 strokes per sec. For the IV study, the tissues were
homogenized by manual cutting and stirring. Depen-
ding on the weight either the whole tissue or sub-
samples (about 0.5 - 1 gram) were used for the Ti analysis.
A homogenized tissue sample was weighed (approxi-
mately 0.5 g) into 15 mL polypropylene tubes (Sarstedt
BV, Etten-Leur, The Netherlands) and 0.5 mL ultrapure
water, 1 mL nitric acid conc. (HNO3) and 0.75 mL
hydrofluoric acid conc. (HF) were added. The tubes
were placed on a block heater (type: Stuart SBH200D;
supplied by Omnilabo, Breda, The Netherlands) and the
mixture was slowly heated to a final temperature of
90°C. The mixture was left for two days at this temperature.
Afterwards, ultrapure water was added to a total volume of
15 mL. With the applied procedure, it was possible to
achieve a good dissociation of the original nanoparticles as
well as digestion of the organic materials.
The Ti measurements were performed at Philips
Innovation Services (Eindhoven, The Netherlands) with a
HR-ICP-MS (ELEMENT XR, Thermo Fisher Scientific,
Breda, The Netherlands), using a set-up with on-line
addition of an internal standard. Two Ti isotopes
were measured in the medium resolution (MR) mode:
while 47Ti(MR) was used for the evaluation, 49Ti(MR)
was used for control. The accurate masses and abun-
dances are: 47Ti (46.95176 atm): 7.3%, respectively 49Ti
(48.94787 atm): 5.5%. The element Ti consists in total of
five naturally abundant isotopes. Nevertheless, the other
three isotopes cannot be used for quantification by HR-
ICPMS due to isobaric and polyatomic interferences.
The instrumental operating conditions were as follows:
RF power 1225 W, cooling gas flow 16 L/min argon,
auxiliary gas flow 0.9 L/min argon, and the sample gas
flow 0.99 L/min argon.
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calibration with internal standard correction using 115In.
As no standard reference materials are available for Ti de-
termination a commercial reference material obtained
from Sero AS (Seronorm™ Trace Elements Whole Blood,
Sero AS, Billingstad, Norway) was analysed according to
the same procedure (L-2 LOT 1003129 contained 18 ±
5 μg/L Ti, and L-3 LOT 1112691 contained 12.8 ± 0.4 μg/L
Ti as provided by the supplier). The limit of detection
(LOD; as 3x STD, n = 20) is estimated from the results ob-
tained for approximately 0.5 g tissue material from control
animals of this study after applying the complete procedure
of digestion and measurement with HR-ICPMS. The LOD
is 0.05 μg Ti/g tissue and the LOQ 0.15 μg Ti/g tissue. For
the tissue series evaluated for Ti content after oral adminis-
tration (for five consecutive days) the LOD was 0.03 μg
Ti/g tissue, and the LOQ 0.09 μg Ti/g tissue.
Kinetic analysis and statistical analysis
Pharmacokinetic analysis was performed on sparse data
by a non-compartmental approach (NCA) using Phoenix
WinNonlin 6.3 software (Pharsight Corporation, Mountain
View, CA, USA) [40]. The analysis focused on the organ
kinetic parameters. Kinetic parameters such as AUC
and apparent elimination rate (β) were determined. The
AUC represents the ‘area under the curve’ of the organ
Ti concentration – time curve, and was calculated using
the linear trapezoidal rule. Apparent elimination rate (β)
was estimated on the terminal phase of the curve by linear
regression of at least 3 points (r2 > 0.95). The apparent
elimination half-life (T1/2el) was calculated by the follow-
ing equation:
T1=2el ¼ 0:693β
Standards errors were only estimated for Cmax and
AUC.
Statistical analysis was performed using the nonpara-
metric Friedman test followed by a pairwise compari-
son using Wilcoxon test to locate potential differences
between groups (i.e. nanomaterials and tissues). The
significance level was 0.05. All statistical analyses were
performed using SYSTAT 13 (Systat Software Inc,
Chicago, USA).
Data evaluation
Data of male and female animals were evaluated sepa-
rately as the difference in dose levels between these
groups (as a result of variation in body weight between
male and female animals) was considered too large. Fur-
ther, the number of sampling periods differed between
male and female animals. However, data within the male
animal groups or within the female animal groups wereanalysed together and the titanium levels (expressed per
tissue or g tissue) were not corrected for differences in
body weight and thus in dose (mg/kg bw) within these
groups. This was considered acceptable, as the intra-
group variation (max. 8%; as a result of intra-group dif-
ferences in body weight) was not expected to exceed the
standard random animal variation.
In groups containing both rats with a Ti level above
and below the LOD, a simulant value was used for mea-
surements below the LOD for estimation of the mean Ti
for all animals investigated. By using a simulant value
the information on animals with a measurement below
the LOD was included in the estimation of the Ti con-
centration per gram organ for the group of animals. The
non-detect samples were assumed to contain Ti concen-
trations equal to half the LOD, in order to be able to use
the information on these tissues in the calculations. A
value of 0 was considered to be too low a value intro-
ducing a bias to a low mean value, whereas using the
LOD itself was considered to result in a bias towards an
overestimation of the tissue Ti content.
For estimating the recovery, the absolute amounts of
titanium per tissue were calculated using the corre-
sponding tissue weights for each animal with the indi-
vidual dose. Second, the amounts of titanium dioxide
dosed via single exposure (2.3 mg TiO2) or repeated ex-
posure (11.5 mg TiO2) were converted into amounts of
titanium (1379 and 6895 μg Ti respectively). This was
done by multiplying the amounts of titanium dioxide
with the ratio of the molecular masses of “titanium” and
“titanium dioxide” (i.e., ~0.60). Finally, the absolute
amounts of titanium in tissue were expressed as percentage
of the total (single or cumulative) administered dose.Additional file
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